SUSAN ABUSHAKRA, M.D.
Chief Medical Officer, Co-Founder
Susan Abushakra, M.D. is a co-founder and has served as our Chief Medical Officer since September 2015. Prior to that, Dr. Abushakra served as the Chief Medical Officer of Transition Therapeutics, Inc., where she led global drug development programs. Previously, Abushakra served as the Chief Medical Officer of Elan/Perrigo Company and as Vice President of Clinical Development at Allergan Inc., where she oversaw several novel neurotoxin programs, including Botox for spasticity and migraine. Dr. Abushakra also held clinical development and global regulatory leadership roles in CNS and Pain programs at Wyeth Pharmaceuticals, Inc. and Eisai Co., Ltd. and AstraZeneca plc. Dr. Abushakra received her M.D. from the American University of Beirut Medical School, Lebanon and completed her neurology residency and fellowship at Johns Hopkins Medical Institutions.